Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]
Awaiting development
Reference number: GID-TA11828
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-January 2027 when we will write to you about how you can get involved.